Is Cannabidiol During Neurodevelopment a Promising Therapy for Schizophrenia and Autism Spectrum Disorders?


. 2021 Feb 4;11:635763.

doi: 10.3389/fphar.2020.635763. eCollection 2020.


Item in Clipboard


Cássio Morais Loss et al. Front Pharmacol. .


Schizophrenia and autism spectrum disorders (ASD) are psychiatric neurodevelopmental disorders that cause high levels of functional disabilities. Also, the currently available therapies for these disorders are limited. Therefore, the search for treatments that could be beneficial for the altered course of the neurodevelopment associated with these disorders is paramount. Preclinical and clinical evidence points to cannabidiol (CBD) as a promising strategy. In this review, we discuss clinical and preclinical studies on schizophrenia and ASD investigating the behavioral, molecular, and functional effects of chronic treatment with CBD (and with cannabidivarin for ASD) during neurodevelopment. In summary, the results point to CBD’s beneficial potential for the progression of these disorders supporting further investigations to strengthen its use.

Keywords: Autism; Cannabidivarin; Prevention; Prodrome; animal models; cannabidiol; neurodevelopmental disorders; schizophrenia.

Conflict of interest statement

JC is a member of the International Advisory Board of the Australian Centre for Cannabinoid Clinical and Research Excellence (ACRE), National Health and Medical Research Council (NHMRC). JC and JH have received travel support to attend scientific meetings and personal consultation fees from BSPG-Pharm. JC, JH, and AZ are coinventors of the patent “Fluorinated CBD compounds, compositions and uses thereof. Pub. No.: WO/2014/108899. International Application No.: PCT/IL2014/050023,” Def. US number Reg. 62193296; July 29, 2015; INPI on August 19, 2015 (BR1120150164927; Mechoulam R, Zuardi AW, Kapczinski F, Hallak JEC, Guimarâes FS, Crippa JAS, Breuer A). Universidade de São Paulo (USP) has licensed this patent to Phytecs Pharm (USP Resolution No. 15.1.130002.1.1) and has an agreement with Prati-Donaduzzi to “develop a pharmaceutical product containing synthetic CBD and prove its safety and therapeutic efficacy in the treatment of epilepsy, schizophrenia, Parkinson’s disease, and anxiety disorders.” JC, JH, and AZ are coinventors of the patent “Cannabinoid-containing oral pharmaceutical composition, method for preparing and using same,” INPI on September 16, 2016 (BR 112018005423-2). The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.


    1. Abel K. M., Drake R., Goldstein J. M. (2010). Sex differences in schizophrenia. Int. Rev. Psychiatry 22 (5), 417–428. 10.3109/09540261.2010.515205 – DOI PubMed
    1. Almeida V., Peres F. F., Levin R., Suiama M. A., Calzavara M. B., Zuardi A. W., et al. (2014). Effects of cannabinoid and vanilloid drugs on positive and negative-like symptoms on an animal model of schizophrenia: the SHR strain. Schizophr. Res. 153 (1–3), 150–159. 10.1016/j.schres.2014.01.039 – DOI PubMed
    1. Alves P., Amaral C., Teixeira N., Correia-da-Silva G. (2020). Cannabis sativa: much more beyond delta(9)-tetrahydrocannabinol. Pharmacol. Res. 157, 104822 10.1016/j.phrs.2020.104822 – DOI PubMed
    1. Amada N., Yamasaki Y., Williams C. M., Whalley B. J. (2013). Cannabidivarin (CBDV) suppresses pentylenetetrazole (PTZ)-induced increases in epilepsy-related gene expression. PeerJ 1, e214 10.7717/peerj.214 – DOI PMC PubMed
    1. American Psychiatric Association. (2013) Diagnostic and statistical manual of mental disorders: DSM-5. 5th edition Arlington, VA: American Psychiatric Association; .

Publication types

L’article Is Cannabidiol During Neurodevelopment a Promising Therapy for Schizophrenia and Autism Spectrum Disorders? est apparu en premier sur Cannabis Belgique.

Comments are closed.